Advertisement

American Journal of Clinical Dermatology

, Volume 6, Issue 5, pp 311–316 | Cite as

Topical Halobetasol Propionate in the Treatment of Plaque Psoriasis

A Review
Review Article

Abstract

Halobetasol propionate (HP) 0.5% ointment and cream are class I topical corticosteroids. We review the efficacy and tolerability of HP for treatment of plaque psoriasis in the English language literature. The efficacy of HP ointment and cream is consistently superior to other super-potent topical corticosteroids. Local adverse events associated with topical HP are similar to those experienced with other super-potent corticosteroids. Combination therapy with calcipotriene (calcipotriol) and tazarotene appears to be superior to monotherapy with topical HP.

Keywords

Psoriasis Topical Corticosteroid Plaque Psoriasis Calcipotriol Tazarotene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34: 911–4PubMedCrossRefGoogle Scholar
  2. 2.
    Lebwohl M. Psoriasis. Lancet. 2003; 361: 1197–204PubMedCrossRefGoogle Scholar
  3. 3.
    Stern RS. Epidemiology of psoriasis. Dermatol Clin. 1995; 13: 717–22PubMedGoogle Scholar
  4. 4.
    Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001; 76: 943–9PubMedGoogle Scholar
  5. 5.
    Federman DG, Froelich CW, Kirsner RS. Topical psoriasis therapy. Am Fam Physician. 1999; 59: 957–962, 964PubMedGoogle Scholar
  6. 6.
    Yawalkar S, Wiesenberg-Boettcher I, Gibson JR, et al. Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. J Am Acad Dermatol. 1991; 25: 1137–44PubMedCrossRefGoogle Scholar
  7. 7.
    Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol. 1991; 25: 1170–4PubMedCrossRefGoogle Scholar
  8. 8.
    Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1175–8PubMedCrossRefGoogle Scholar
  9. 9.
    Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1153–6PubMedCrossRefGoogle Scholar
  10. 10.
    Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1145–8PubMedCrossRefGoogle Scholar
  11. 11.
    Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1149–52PubMedCrossRefGoogle Scholar
  12. 12.
    Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991; 25: 1166–9PubMedCrossRefGoogle Scholar
  13. 13.
    Katz HE Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991; 183: 269–74PubMedCrossRefGoogle Scholar
  14. 14.
    Brunner N, Yawalkar S. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991; 25: 1160–3PubMedCrossRefGoogle Scholar
  15. 15.
    Datz B, Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991; 25: 1157–60PubMedCrossRefGoogle Scholar
  16. 16.
    Kantor I, Cook PR, Cullen SI, et al. Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses. J Am Acad Dermatol. 1991; 25: 1184–6PubMedCrossRefGoogle Scholar
  17. 17.
    Yawalkar SJ, Schwerzmann L. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. J Am Acad Dermatol. 1991; 25: 1163–6PubMedCrossRefGoogle Scholar
  18. 18.
    Watson WA, Kalb RE, Siskin SB, et al. The safety of halobetasol 0.05% ointment in the treatment of psoriasis. Pharmacotherapy. 1990; 10: 107–11PubMedGoogle Scholar
  19. 19.
    Walsh P, Aeling JL, Huff L, et al. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993; 29: 501–3PubMedCrossRefGoogle Scholar
  20. 20.
    Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function. J Am Acad Dermatol. 1987; 16: 804–11PubMedCrossRefGoogle Scholar
  21. 21.
    Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998; 39: 447–50PubMedCrossRefGoogle Scholar
  22. 22.
    Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996; 35: 268–9PubMedCrossRefGoogle Scholar
  23. 23.
    Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 1997; 37: S55–8PubMedCrossRefGoogle Scholar
  24. 24.
    Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol. 2001; 2 (2): 95–120PubMedCrossRefGoogle Scholar
  25. 25.
    Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003; 48: 48–54PubMedCrossRefGoogle Scholar
  26. 26.
    Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002; 147: 316–23PubMedCrossRefGoogle Scholar
  27. 27.
    Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol. 1998; 139: 649–54PubMedCrossRefGoogle Scholar
  28. 28.
    Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999; 107: 595–605PubMedCrossRefGoogle Scholar
  29. 29.
    Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high-or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002; 6: 95–102PubMedCrossRefGoogle Scholar
  30. 30.
    Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol. 2000; 42: 1008–11PubMedCrossRefGoogle Scholar
  31. 31.
    Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998; 39: 590–6PubMedCrossRefGoogle Scholar
  32. 32.
    Lebwohl M, Poulin Y. Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol. 1998; 39: S139–43PubMedCrossRefGoogle Scholar
  33. 33.
    Gollnick H, Menter A. Combination therapy with tazarotene plus a topical cortico-steroid for the treatment of plaque psoriasis. Br J Dermato. 1999; 140 Suppl. 54: 18–23CrossRefGoogle Scholar
  34. 34.
    Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000; 22: 1225–38PubMedCrossRefGoogle Scholar
  35. 35.
    Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis. 2000; 66: 4–11PubMedGoogle Scholar
  36. 36.
    Lebwohl M. Psoriasis. In: Lebwohl MG, Heymann W, Berth-Jones J, et al., editors. Treatment of Skin Disease: Comprehensive Treatment Strategies. New York: Mosby International, 2002: 533–43Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of DermatologyBaylor College of MedicineHoustonUSA

Personalised recommendations